Tirzepatide GLP-1 The drug is known to improve sleep apnea in people with both obstructive sleep apnea (OSA) and obesity, but not all patients benefit equally.
Now, new research presented at the 2026 ATS International Congress narrows down which patients are likely to have the best treatment outcomes.
Patients in this “strong response” subtype experienced nearly twice as much improvement in sleep apnea as other patients. The findings could help doctors provide more personalized treatment and give patients clearer expectations for their sleep health. This is the first time that a subgroup has been identified that has a strong response to this treatment.
We are excited about these discoveries. Because these findings provide an opportunity to share with patients that you have the characteristics that put you in a group of patients who respond significantly to tirzepatide reduction therapy. Or, conversely, “There are characteristics that suggest you may still need additional treatment.” ”
Dr. Scott Sands, first author, Associate Professor of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston
For this study, researchers conducted a secondary analysis of data from previous clinical trials of tirzepatide in patients with OSA and obesity.
They identified a “strongly responsive endotype,” a subgroup of patients who had significantly better outcomes than other patients. These patients were younger, mildly obese, and also had certain characteristics associated with the underlying cause of their sleep apnea, including more severe upper airway collapse, greater instability of respiratory control (called “high loop gain”), and a tendency to wake more easily due to airflow obstruction.
Dr. Sands said the finding that greater loop gain was a predictor of treatment efficacy was initially surprising. However, further studies found that tirzepatide treatment helped improve both respiratory instability and upper airway collapse, suggesting that this may be an additional target for treatment.
Dr. Sands noted that the findings will help fill gaps in doctors’ ability to counsel patients and identify those who would benefit most from treatment.
“Currently, clinicians can only point to an average treatment response, showing that, on average, patients can expect about half the severity of their sleep apnea than they would with a placebo,” he noted. “Ultimately, we want to take the guesswork out of this experience for patients and their sleep physicians.”
Next, team members hope to continue the research in future studies examining the consequences of OSA across various pharmacological and non-pharmacological weight loss therapies, he added.
sauce:
American Thoracic Society
